{
    "clinical_study": {
        "@rank": "15", 
        "brief_summary": {
            "textblock": "To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in\n      HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single\n      doses and then, after FDA review, daily doses for 7 days."
        }, 
        "brief_title": "Phase I/II Study of Curdlan Sulfate", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested.\n      In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or\n             other malignancy.\n\n          -  CD4 count < 500 cells/mm3.\n\n          -  No critical illness that would shorten life expectancy to < 16 weeks.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral or other experimental therapies.\n\n          -  Anticoagulants.\n\n          -  Steroids.\n\n          -  Cytotoxic or immunosuppressive agents.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiotherapy.\n\n        Patients with the following prior condition are excluded:\n\n        History of heparin sensitivity.\n\n        Prior Medication:\n\n        Excluded within 1 month prior to study entry:\n\n          -  Antiretroviral or other experimental therapies.\n\n          -  Anticoagulants.\n\n          -  Steroids.\n\n          -  Cytotoxic or immunosuppressive agents.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiotherapy within 1 month prior to study entry. Active IV drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002100", 
            "org_study_id": "127A", 
            "secondary_id": "LCPL 92-1-28"
        }, 
        "intervention": {
            "intervention_name": "Curdlan sulfate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Curdlan sulfate"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "curdlan sulfate"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94109"
                }, 
                "name": "ViRx Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I/II Study of Curdlan Sulfate", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "7996061", 
            "citation": "Gordon M, Guralnik M, Kaneko Y, Mimura T, Baker M, Lang W. A phase I study of curdlan sulfate--an HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes. J Med. 1994;25(3-4):163-80."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002100"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AJI Pharma USA", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1994"
    }, 
    "geocoordinates": {
        "ViRx Inc": "37.775 -122.419"
    }
}